Incorporation of Pharmacokinetic and Pharmacodynamic Data into Risk Assessments

Toxicology Mechanisms and Methods

Volumn 14, Issue 3, 2004, Pages 145-158

  Lipscomb, John C ^a   Meek, M E ^b   Krishnan, Kannan ^c   Kedderis, Gregory L ^d   Clewell, Harvey ^e   Haber, Lynne ^f  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b HEALTH CANADA   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Independent Consultant   (United States)

^e ENVIRON INTERNATIONAL CORPORATION   (United States)

^f Toxicology Excellence for Risk Assessment   (United States)

Author keywords

Chemical Specific Adjustment Factors (CSAF); Enzyme Kinetics; Human Variability; In Silico Predictions; In Vitro Studies; Interspecies Differences; Metabolism; Risk Assessment; Toxicodynamics; Toxicokinetics; Uncertainty Factors

Indexed keywords

ALIPHATIC HYDROCARBON; DICHLOROMETHANE; ESTER DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; PHENOL DERIVATIVE; POLYCHLORINATED BIPHENYL; SULFONAMIDE; XENOBIOTIC AGENT;

ALGORITHM; ANATOMY; BIOCHEMISTRY; COMPUTER MODEL; EVALUATION; LIVER METABOLISM; METABOLISM; METHODOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; RISK ASSESSMENT; TOXICOKINETICS; TOXICOLOGY;

EID: 1942502174     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376520490429382     Document Type: Review

References (54)

1. Abraham, M., Kamlet, M. J., Taft, R. W., Doherty, R. M., and Weathersby, P. K. 1985. Solubility properties in polymers and biological media. 2. The correlation and prediction of the solubilities of nonelectrolytes in biological tissues and fluids. J. Med. Chem. 28:865-870.
2. Abraham, M. H., and Weathersby, P. K. 1994. Hydrogen bonding. 30. Solubility of gases and vapors in biological liquids and tissues. J. Pharm. Sci. 83:1450-1456.
3. Arias, I. M., Popper, H., Schachter, D., and Shafritz, D. A. 1982. The Liver: Biology and Pathobiology, New York: Raven Press.
4. Arms, A. D., and Travis, C. C. 1988. Reference physiological parameters in pharmacokinetic modeling, US EPA/600/6-88/004, Final Report, NTIS, PB88-196019.
5. Billings, R. E., McMahon, R. E., Ashmore, J., and Wagle, S. R. 1977. The metabolism of drugs in isolated rat hepatocytes: A comparison with in vivo drug metabolism and drug metabolism in subcellular liver fractions. Drug Metab. Dispos. 5:518-526.
6. Clewell, H. J., and Andersen, M. E. 1994. Physiologically based pharmacokinetic modeling and bioactivation of xenobiotics. Toxicol. Ind. Health 10:1-24.
7. Clewell, H. J., III and Andersen, M. E. 1996. Use of Physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111:315-329.
8. Clewell, H. J., Gentry, P. R., Gearhart, J. M., Covington, T. R., Banton, M. I., and Andersen, M. E. 2001. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol. Sci. 63:160-172.
9. Clewell, H. J., Gentry, P. R., Covington, T. R., Sarangapani, R., and Teeguarden, J. G. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. (in press).
10. Clewell, H. J., Teeguarden, J., McDonald, T., Sarangapani, R., Lawrence, G., Covington, T., Gentry, P. R., and Shipp, A. M. 2002. Review and evaluation of the potential impact of age and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32:329-389.
11. Clewell, R. A., and Gearhart, J. M. 2002. Pharmacokinetics of toxic chemicals in breast milk: Using PBPK models to predict infant exposure. Environ. Health Perspect. 110:A333-337.
12. Connell, D. W., Braddock, R. D., and Mani, S. V. 1993. Prediction of partition coefficients of liphoilic compounds in the air-mammal tissue system. Sci Total Environ. Suppl. 2:1383-1396.
13. DeJongh, J., Verhaar, H. J., and Hermens, J. L. 1997. A quantitative property-property relationship QPPR approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch. Toxicol. 72:17-25.
14. Ekins, S., Murray, G. I., Burke, M. D., Williams, J. A., Marchant, N. C., and Hawksworth, G. M. 1995. Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. Drug Metab. Dispos. 23:1274-1279.
15. Gearhart, J. M., Mahle, D. A., Greene, R. J., Seckel, C. S., Flemming, C. D., Fisher, J. W., Clewell, H. J. 1993. Variability of physiologically-based pharmacokinetic (PB-PK) model parameters and their effects on PB-PK model predictions in a risk assessment for perchloroethylene. Toxicol. Lett. 68:131-144.
16. Gentry, P. R., Covington, T. R., and Clewell, H. J. 2003. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Reg. Toxicol. Pharmacol. 38(1):1-16.
17. Gentry, P. R., Hack, C. E., Haber, L., Maier, A., and Clewell, H. J. 2002. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: Examples with warfarin and parathion. Toxicol. Sci. 70:120-139.
18. Gearhart, J. M., Jepson, G. W., Clewell, H. J., Andersen, M. E., and Connoly, R. B. 1994. "Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters." Environ. Health Perspect. 102(Suppl 11):51-60.
19. Haber, L. T., Maier, A., Gentry, P. R., Clewell, H. J., and Dourson, M. L. 2002. Genetic polymorphisms in assessing interindividual variability in delivered dose. Reg. Tox. Pharm. 35:177-197.
20. Hansch, C., and Leo, A. 1995. QSAR in metabolism, In Exploring QSAR: Fundamentals and applications in chemistry and biology, eds. C. Hansch, and A. Leo, 299-343. ACS professional reference book of American Chemical Society, Washington DC.
21. Houston, J. B. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469-1479.
22. International Commission on Radiological Protection (ICRP). 1975. In Report of the task Group on Reference Man, eds. W. S. Snyder, M. J. Cook, L. R. Karhausen, E. S. Nasset, G. P. Howells, and I. H. Tipton. Pergamon Press: Oxford, UK.
23. International Programme on Chemical Safety (IPCS). 1994 Environmental Health Criteria No. 170: Assessing Human Health Risks of Chemicals: Derivation of Guidance Values for Health-based Exposure Limits. World Health Organization, Geneva.
24. International Programme on Chemical Safety (IPCS) 2001. Guidance Document for the Use of Data in Development of Chemical-Specific Adjustment Factors (CSAFs) for Interspecies differences and Human Variability in Dose/Concentration-Response Assessment. World Health Organization, Geneva. http://www.ipcsharmonize.org
25. Kalizan, R., and Markuszewski, M. 1996. Brain/blood distribution described by a combination of partition coefficients and molecular mass. Int. J. Pharmacol. 145:9-16.
26. Kaneko, T., Wang, P. Y., and Sato, A. 1994. Partition coefficients of some acetate esters and alcohol in water, blood, olive oil, and rat tissues. Occup. Environ. Med. 51:68-72.
27. Kedderis, G. L. 1997a. Toxicokinetics: Biotransformation of Toxicants. In Comprehensive Toxicology eds. I. G. Sipes, C. A. McQueen, and A. J. Gandolfi, Volume I General Principles. ed. J. Bond, 135-148. Oxford: Elsevier Science Ltd.
28. Kedderis, G. L. 1997b. Extrapolation of In Vitro Enzyme Induction Data to Humans In Vivo, Chem.-Biol. Interact. 107:109-121.
29. Kedderis, G. L., Carfagna, M. A., Held, S. D., Batra, R., Murphy, J. E., and Gargas, M. L. 1993. Kinetic Analysis of Furan Biotransformation by F-344 Rats In Vivo and In Vitro. Toxicol. Appl. Pharmacol. 123:274-282.
30. Kedderis, G. L., and Held, S. D. 1996. Prediction of furan pharmacokinetics from hepatocyte studies: Comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol. Appl. Pharmacol. 140:124-130.
31. Krishnan, K., and Andersen, M. E. 2001. Physiologically-based Phamacokinetic Modeling in Toxicology. In Principles and Methods in Toxicology ed. W. Hayes, 193-141. New York: Taylor & Francis.
32. Laass, W. 1987. Estimation of blood/air partition coefficients of organic solvents, in QSAR in drug design and toxicology, eds. D. Hadzi, and B. Jerman-Balzic, (pp. 131-134). Elsevier Science Publishers: Amsterdam.
33. Lipscomb, J. C., Garrett, C. M., and Snawder, J. E. 1997. Cytochrome P450-dependent metabolism of trichloroethylene: interindividual differences in humans. Toxicol. Appl. Pharmacol. 142:311-318.
34. Lipscomb, J. C., Teuschler, L. K., Swartout, J., Popken, D., Cox, T., and Kedderis, G. L. 2003a. The impact of cytochrome P450 2E1-dependent metabolic variance on a risk relevant pharmacokinetic outcome in humans. Risk Analysis 23:1221-1238.
35. Lipscomb, J. C., Teuschler, L. K., Swartout, J. C., Striley, C. A. F., and Snawder, J. E. 2003b. Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol. Mech. Methods. 13:45-51.
36. Lipscomb, J. C., and Kedderis, G. L. 2002. Incorporating human interindividual biotransformation variance in health risk assessment. Sci. Total Environ. 288:13-21.
37. Lombardo. F., Blake, J. F., and Curatolo, W. J. 1996. Computation of brain-blood partitioning of organic solutes via free energy calculations. J. Med. Chem. 39:4750-4755.
38. Meek, M. E. 2001. Categorical Default Uncertainty Factors-Interspecies variation and adequacy of database. Human Ecol. Risk Assess. 7:157-163.
39. Meek, M. E., Ohanian, E., Renwick, A., Naumann, B., Lake, B., Vu, V., and Dourson, M. 1999. Guidelines for application of data-derived uncertainty factors in risk assessment. Report of a Meeting by Toxicology Excellence for Risk Assessment for U.S. EPA/Health Canada, Washington, March 25th-26th.
40. Meek, M. E., Ohanian, E., Renwick, A., Naumann, B., Lake, B., Vu, V., and Dourson, M. 2001. Guidelines for application of chemical-specific adjustment factors in dose/concentration assessment. Comments Toxicol. 7:575-590.
41. Naumann, B. D., Silverman, K. C., Dixit, R., Faria, E. C., and Sargent, E. V. 2001. Case Studies of categorical data-derived adjustment factors. Human Ecol. Risk Asses. 7:61-106.
42. Northrop, D. B. 1983. Fitting enzyme-kinetic data to V/K Analyt. Biochem. 132:457-461.
43. Parham, F. M., Kohn, M. C., Mathews, H. B., DeRosa, C., and Portier, C. J. 1997. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated byphenyls. Toxicol. Appl. Pharmacol. 144:340-347.
44. Perbellini, L., Brugnone, F., Caretta, D., and Maranelli, G. 1985. Partition coefficients of some industrial aliphatic hydrocarbons (C5-C7) in blood and human tissues. Br. J. Ind. Med. 42:162-167.
45. Pelekis, M. L., Poulin, P., and Krishnan, K. 1995. An approach for incorporating tissue composition data into physiologically based pharmacokinetic models. Toxicol. Ind. Health 11:511-522.
46. Poulin, P., and Krishnan, K. 1996. A mechanistic algorithm for predicting blood: Air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicol. Appl. Pharmacol. 136:131-137.
47. Renwick, A. G. 1993. Data-derived safety (uncertainty) factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 10:275-305.
48. Renwick, A. G., and Lazarus, N. R. 1998. Human variability and noncancer risk assessment-An analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 27(1 Pt 2):3-20.
49. Sarangapani, R., Gentry, P. R., Covington, T. R., Teeguarden, J. G., and Clewell, H. J. 2003. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal. Toxicol. 10:987-1016.
50. Seydel, J. K., and Schaper, K. J. 1982. Quantitative structure-pharmacokinetic relationships and drug design. Pharmacol. Ther. 15:131-182.
51. Sirica, A. E., and Pitot, H. C. 1980. Drug metabolism and effects of carcinogens in cultured hepatic cells, Pharmacol. Rev. 31:205-228.
52. Snawder, J. E., and Lipscomb, J. C. 2000. Interindividual variance of cytochrome P450 forms in human hepatic microsomes: Correlation of individual forms with xenobiotic metabolism and implications for risk assessment. Regul. Toxicol. Pharmacol. 32:200-209.
53. US Environmental Protection Agency (US EPA) Office of Pollution Prevention Toxics and Syracuse Research Corporation. 2003. Estimation Program Interface (EPI) Suites. Available online at: http://www.epa.gov/opptintr/exposure/docs/episuite.htm.
54. Worboys, P. D., Brennan, B., Bradbury, A., and Houston, J. B. 1996. Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition, Xenobiotica 26:897-907.